Summary & Overview
HCPCS G0479: Presumptive Drug Test by Instrumented Chemistry Analyzers
HCPCS Level II code G0479 denotes presumptive drug testing performed with instrumented chemistry analyzers and covers any number of drug classes and devices per date of service. The code includes sample validation when performed and encompasses a range of analytic methods such as immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, and GC mass spectrometry. This code is significant for clinical laboratories and diagnostic providers because it standardizes reporting for multi-class presumptive drug screens using automated instrumentation.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, common sites and service settings, and the components included in the code definition. The publication also outlines typical billing considerations and common modifiers where available. The material is intended to inform billing staff, laboratory managers, and policy analysts about how the code is defined, what services it covers, and the national payer landscape relevant to presumptive instrumented drug testing.
Billing Code Overview
HCPCS Level II code G0479 describes a presumptive drug test performed using instrumented chemistry analyzers. The procedure covers testing for any number of drug classes and may use multiple devices or analytical methods, including immunoassay, enzyme assay, time-of-flight (TOF), MALDI, LDTD, DESI, DART, GHPC, and GC mass spectrometry. The service description also specifies that sample validation, when performed, is included in the code, and billing is per date of service.
Service type: Presumptive drug testing using instrumented chemistry analyzers
Typical site of service: Clinical laboratories, hospital laboratories, outpatient laboratory collection sites, and other diagnostic testing facilities
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient presents to an outpatient addiction medicine clinic for routine monitoring of a medication-assisted treatment program. The clinician orders a laboratory presumptive drug screen performed by an instrumented chemistry analyzer using immunoassay to verify recent substance use and guide treatment decisions. A urine sample is collected, labeled, and sent to the onsite laboratory; the lab performs the presumptive immunoassay panel, documents sample validity (creatinine, pH, specific gravity) when performed, and generates results for the same date of service. Results are reviewed by the treating clinician and placed in the medical record to document adherence and inform counseling. Typical workflow includes patient check-in, specimen collection by trained staff, accessioning in the lab, instrumented analysis (immunoassay or other listed analyzer), verification by laboratory personnel, and clinician review. The service is commonly delivered in outpatient hospital labs, independent clinical laboratories, office-based labs supporting addiction, pain management, or employer drug screening programs, and community mental health centers. Modifier TC is used when reporting the technical component of this laboratory service separately from the professional interpretation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
TC | Technical component — equipment, supplies, and technical staff | Use when billing only the laboratory technical component for the instrumented presumptive drug test |